- Conditions
- Venous Thromboembolic Disease, Pulmonary Embolism and Thrombosis, Deep Vein Thrombosis, Hospitalism
- Interventions
- EHR (electronic health record) alert, No EHR (electronic health record) alert
- Other
- Lead sponsor
- Scott C. Woller, MD
- Other
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 152,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Murray, Utah
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 37
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Atrial Fibrillation (AF), VTE
- Interventions
- PAUSE Perioperative DOAC Management, ASRA Perioperative DOAC Management
- Other
- Lead sponsor
- McMaster University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 920 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 6
- States / cities
- Hartford, Connecticut • Evanston, Illinois • Boston, Massachusetts + 3 more
- Conditions
- Treatment of Venous Thromboembolism in Cancer Patients, Prophylaxis of Recurrent Venous Thromboembolism in Cancer Patients
- Interventions
- Rivaroxaban (Xarelto, BAY59-7939), Low molecular weight heparin (LMWH), Direct Oral Anticoagulants (DOAC)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,708 participants
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Multiple Locations, Connecticut
- Conditions
- Cardiovascular Diseases, Venous Thromboembolism, Atrial Fibrillation, Bleeding, Stroke
- Interventions
- Clinical Pharmacist Intervention
- Other
- Lead sponsor
- University of Massachusetts, Worcester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 561 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Worcester, Massachusetts
- Conditions
- Intracranial Hemorrhage
- Interventions
- Use of fixed-dosed 4F-PCC
- Procedure
- Lead sponsor
- Methodist Health System
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Atrial Fibrillation, Stroke, Bleeding
- Interventions
- Antiplatelet-only strategy, Oral Anticoagulant plus background antiplatelet therapy
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 51
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Stanford, California + 40 more
- Conditions
- Splanchnic Vein Thrombosis, Cerebral Vein Thrombosis, Ovarian Vein Thrombosis, Renal Vein Thrombosis, Retinal Vein Thrombosis
- Interventions
- Direct Oral Anticoagulants
- Drug
- Lead sponsor
- University of Malta
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Blood Clot
- Interventions
- Rivaroxaban, Apixaban, Edoxaban, Dabigatran, Warfarin, Dalteparin, Enoxaparin, Fondaparinux
- Drug
- Lead sponsor
- Alliance Foundation Trials, LLC.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 811 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 151
- States / cities
- Chula Vista, California • Fremont, California • Fresno, California + 104 more
- Conditions
- Carcinoma, Non-small-Cell Lung
- Interventions
- Amivantamab, Lazertinib, Carboplatin, Pemetrexed, Direct Oral Anticoagulant (DOAC), Low Molecular Weight Heparin (LMWH)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 520 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 26
- States / cities
- La Jolla, California • Orange, California • Stanford, California + 21 more
- Conditions
- Bleeding From Teeth, Bleeding Prophylaxis
- Interventions
- Tranexamic acid
- Drug
- Lead sponsor
- Hyloris Developments
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Loma Linda, California • Stamford, Connecticut • Millcreek, Utah + 1 more
- Conditions
- Venous Thrombosis, Neoplasms
- Interventions
- Heparin, Low-Molecular-Weight, or direct oral anticoagulants
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 3
- States / cities
- Minneapolis, Minnesota • Columbus, Ohio • Milwaukee, Wisconsin
- Conditions
- Drug-Related Side Effects and Adverse Reactions, Treatment Failure
- Interventions
- Not listed
- Lead sponsor
- Cipherome, Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Santa Clara, California
- Conditions
- Hypercoagulable States
- Interventions
- Observational
- Other
- Lead sponsor
- Methodist Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Acute Major Bleeding
- Interventions
- Octaplex
- Drug
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 10
- States / cities
- Torrance, California • Gainesville, Florida • West Palm Beach, Florida + 6 more
- Conditions
- Blood Loss, Surgical, Coagulation Disorder
- Interventions
- Reltodecacog alfa, Usual Pharmacological Care
- Drug
- Lead sponsor
- VarmX B.V.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 19
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Stanford, California + 14 more
- Conditions
- Cancer, VTE (Venous Thromboembolism)
- Interventions
- Apixaban 2.5 mg twice daily, Apixaban 5 mg once daily, No anticoagulation
- Drug
- Lead sponsor
- University of Vermont
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 996 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2035
- U.S. locations
- 1
- States / cities
- Burlington, Vermont
- Conditions
- Uterine Hemorrhage
- Interventions
- Direct oral anticoagulant (DOACs), Warfarin
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 961,985 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Titusville, New Jersey
- Conditions
- Radial Artery Occlusion
- Interventions
- Rivaroxaban 15 MG Oral Tablet [Xarelto]
- Drug
- Lead sponsor
- Ottawa Heart Institute Research Corporation
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 930 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Coagulation
- Interventions
- Whole Blood Clotting Time
- Device
- Lead sponsor
- Perosphere Technologies Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 4
- States / cities
- Danbury, Connecticut • Rockville, Maryland • Denville, New Jersey + 1 more
- Conditions
- Ventricular Tachycardia, Premature Ventricular Contraction, Stroke
- Interventions
- DOAC, Aspirin
- Drug
- Lead sponsor
- Kansas City Heart Rhythm Institute
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 4
- States / cities
- Kansas City, Kansas • Overland Park, Kansas • The Bronx, New York + 1 more
- Conditions
- Atrial Fibrillation (AF)
- Interventions
- Not listed
- Lead sponsor
- McMaster University
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 1,780 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 4
- States / cities
- Evanston, Illinois • Detroit, Michigan • Great Neck, New York + 1 more
- Conditions
- Acute Myocardial Infarction
- Interventions
- Not listed
- Lead sponsor
- Methodist Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Acute Ischemic Stroke
- Interventions
- Intravenous tenecteplase (TNK), Placebo
- Drug
- Lead sponsor
- Hackensack Meridian Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 660 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2032
- U.S. locations
- 1
- States / cities
- Neptune City, New Jersey
- Conditions
- Pulmonary Embolism, Venous Thromboembolism, Atrial Fibrillation
- Interventions
- New-prescription Alert, New-prescription Alert with referral option, Existing-prescription notification to prescriber, Existing-prescription notification to pharmacist
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- Not listed
- Enrollment
- 306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan